Vivo Capital closes on $740m for third cycle of evergreen public fund

The fund's private markets-style structure 'allows us to apply a venture capital mindset to publicly traded biotech companies,' says managing partner Gaurav Aggarwal.

FundraisingManagersNorth AmericaUSFundraisingHealthcareLife SciencesRegulation